SCHEMBL7146591

SCHEMBL7146591

OCCOP(O)(O)=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28962440 0.82
SCHEMBL899753 0.73
SCHEMBL9242713 0.73
SCHEMBL3501699 0.73
SCHEMBL27530840 0.71
SCHEMBL6263876 0.71 LPAR3 (0.40)
SCHEMBL5585483 0.71
SCHEMBL600792 0.71
SCHEMBL39567 0.69
SCHEMBL26209 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600965-B2 Modified double stranded oligonucleotide ALNYLAM PHARMACEUTICALS, INC. (US) 2026-04-14 US disclosed
US-12584130-B2 Angiotensinogen (AGT) iRNA compositions and methods of use thereof ALNYLAM PHARMACEUTICALS, INC. (US) 2026-03-24 US disclosed
US-20260035702-A1 PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF ALNYLAM PHARMACEUTICALS, INC. (US) 2026-02-05 US disclosed
US-12460206-B2 PCSK9 iRNA compositions and methods of use thereof ALNYLAM PHARMACEUTICALS, INC. (US) 2025-11-04 US disclosed
US-20250333737-A1 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF REGENERON PHARMA (US) 2025-10-30 US disclosed
US-12416006-B2 Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof ALNYLAM PHARMACEUTICALS, INC. (US) 2025-09-16 US disclosed
US-20250277218-A1 METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER BANK OF AMERICA, N.A. 2025-09-04 US disclosed
US-20250270562-A1 BIS-RNAI COMPOUNDS FOR CNS DELIVERY BANK OF AMERICA, N.A. 2025-08-28 US disclosed
US-20250257351-A1 REVERSIR TM COMPOUNDS ALNYLAM PHARMACEUTICALS, INC. (US) 2025-08-14 US disclosed
US-12359201-B2 17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof REGENERON PHARMACEUTICALS, INC. (US) 2025-07-15 US disclosed
EP-2929031-A1 PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF Alnylam Pharmaceuticals, Inc. (US) 2015-10-14 EP disclosed
WO-2014089313-A1 PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF ALNYLAM PHARMACEUTICALS (US) 2014-06-12 WO disclosed
US-20030065146-A1 Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing COOK PHILLIP D (US) 2003-04-03 US disclosed
US-6448373-B1 INHIBITORS OF ENZYMES SUCH AS PHOSPHOLIPASE A2; TREATMENT OF INFLAMMATORY DISEASES INCLUDING ATOPIC DERMATITIS AND INFLAMMATORY BOWEL DISEASE ISIS PHARMACEUTICALS, INC. 2002-09-10 US disclosed
EP-0739351-B1 MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM ISIS PHARMACEUTICALS INC (US) 2002-04-10 EP disclosed
US-5886177-A ETHYLENE GLYCOL MONOMERS JOINED VIA STANDARD PHOSPHATE LINKAGES INCLUDING PHOSPHOROTHIOATE, PHOSPHODIESTER, AND PHOSPHORAMIDATE LINKAGES; USEFUL FUNCTIONAL GROUPS INCLUDE NUCLEOBASES AS WELL AS POLAR GROUPS, HYDROPHOBIC GROUPS ISIS PHARMACEUTICALS, INC. (US) 1999-03-23 US disclosed
EP-0739351-A4 MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM ISIS PHARMACEUTICALS INC (US) 1998-10-21 EP disclosed
EP-0739351-A1 MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 1996-10-30 EP disclosed
WO-1995018820-A1 MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 1995-07-13 WO disclosed
US-4416830-A Polyether phosphoric acids or esters GESELLSCHAFT FUR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) (DE) 1983-11-22 US disclosed